產品詳情
簡單介紹：
Anti-Elastin抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-Elastin抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-Elastin
Cat. Number:
Anti-Elastin抗體KL-11057R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Elastic fibers, which are comprised primarily of elastin, endow loose connective tissue with a resilience that compliments the tensile strength of collagenous fibers. Elastin is the main component of the extracellular matrix of arteries, and it performs a regulatory function during arterial development by controlling proliferationAnti-Elastin抗體 of smooth muscle and stabilizing arterial structure. Elastin is composed largely of glycine, proline, and other hydrophobic residues, and it contains multiple lysine-derived crosslinks, such as desmosines, which link individual polypeptide chains into a rubber-like network. During aging, the elasticity of connective tissue becomes reduced because of the cross-linking of collagenous fibers with elastin. Deficiencies of elastin are associated with multiple disorders, such as supravalvular aortic stenosis and Williams-Beuren syndrome. The human elastin gene maps to chromosome 7q11.23.
Also known as:
Elastin; ELN; SVAS; Tropoelastin;Anti-Elastin抗體 WBS; WS.ELN_BOVIN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, .
●
Immunogen: KLH conjugated Anti-Elastin抗體synthetic peptide derived from bovine Elastin.
●
Predicted Molecular Weight: 80kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-Elastin抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
